VTL Vital Therapies Inc

Vital Therapies to Present at the 19th International Liver Support Meeting

Vital Therapies to Present at the 19th International Liver Support Meeting

SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that additional data from its VTL-308 clinical trial will be presented today at the 19th International Liver Support Meeting in Rostock-Warnemunde, Germany.  The presentation, titled "Update on ELAD Study VTL-308", will be made by Nikolaos T. Pyrsopoulos, M.D., Ph.D., Professor and Chief, Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School.

Slides from the presentation will be available on our website in the "Research and Clinical Development" section.

Investor Contact:



Vital Therapies, Inc. 

Investor Relations

858-673-6840

EN
29/09/2018

Underlying

VTLVital Therapies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vital Therapies Inc

 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarte...

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019 SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:  VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April. In connection with the closing of the transaction, Vital Therapies will change its name to Immun...

April 10, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies, Inc. Announces Stockholder Approval of Business Combi...

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:  VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today.  Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval. “We...

April 4, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies Reminds Stockholders to Vote For the Proposed Busines...

Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go ForwardEvery Vote is Important to Avoid Delay in Completion of the Business Combination SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholder...

March 27, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommen...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Vital Therapies stockholders vote “FOR” the proposed business combination with Immunic AG and the related proposals in the Company’s proxy statement/prospectus for the special meeting of its sto...

March 25, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies Announces 2018 Financial Results

Vital Therapies Announces 2018 Financial Results SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the year ended December 31, 2018. Recent Developments On January 6, 2019, we entered into an exchange agreement (the “Exchange Agreement”), with Immunic AG, or Immunic, and all of the current shareholders of Immunic.  Under this agreement, all Immunic shareholders will exchange all of their Immuni...

March 4, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch